Podcasts about RET

Kevin Gallagher, CTV News; Maj.-Gen. (Ret'd) Denis Thompson, former NATO Task Force Commander in Kandahar; Annie Bergeron-Oliver, CTV News; Dr. Alika Lafontaine, Canadian Medical Association President; Glen McGregor, CTV News; Karen Hogan, Auditor General; Ahmed Hussen, Housing Minister; Joy Malbon, CTV News; Bob Fife, the Globe and Mail; Emilie Nicolas, Le Devoir; and Guy Saint-Jacques, former Canadian Ambassador to China.

Today, we're celebrating our state Veterans with stops in Hattiesburg for the city's Veterans Day Parade and Ceremony festivities, happening today, with the Chair of the Hattiesburg Veteran of the Year Selection Committee, Ret. Col. Shelia Varnado, then we'll swing by Hernando for their 2022 Veterans Day Parade and Luncheon events today with Carolyn Young, before jetting off to the Raymond/John Bell Williams Airport to learn more about Free Flights for Veterans happening tomorrow with Hangar 360 Aircraft Services owner, John Mosely.Next Stop, Mississippi is your on-air source for information about upcoming events and attractions across the state. Get to know the real Mississippi! To view or submit events: www.mpbonline.org/community/mississippi-events/. Hosted on Acast. See acast.com/privacy for more information.

Did you know that all branches of the U.S. military are struggling to recruit young people to serve our country? Or that the U.S. Army missed their goal this year by 15,000 soldiers? On today's edition of Family Talk, Lt. Gen. (Ret.) Jerry Boykin continues speaking on the moral decline in America's armed forces and its dangerous effect. Due to the focus and embrace of political woke ideology, this decorated warrior states that there are too many soldiers who are ill-equipped today for the rigors of combat. To support this ministry financially, visit: https://www.oneplace.com/donate/707/29

Guests: Tim Lammers (51:57), Ret. Lt. Col. Bob Stephenson (1:11:33), Neil Candelora (1:31:28), Sam Ekstrom (1:53:00). The KQ Morning Show - Originally aired on November 10, 2022See omnystudio.com/listener for privacy information.

According to Lt. Gen. (Ret.) Jerry Boykin, America's military is in a steep decline. Sadly, it has been transformed by secular politics. On today's edition of Family Talk, Lt. Gen. (Ret.) Boykin explains that for every minute that young recruits are indoctrinated with this woke ideology, they're spending less time training to defend our country. Consequently, fewer young people are joining the military. It's long overdue for our armed forces to be restored back to greatness. To support this ministry financially, visit: https://www.oneplace.com/donate/707/29

According to Lt. Gen. (Ret.) Jerry Boykin, America's military is in a steep decline. Sadly, it has been transformed by secular politics. On today's edition of Family Talk, Lt. Gen. (Ret.) Boykin explains that for every minute that young recruits are indoctrinated with this woke ideology, they're spending less time training to defend our country. Consequently, fewer young people are joining the military. It's long overdue for our armed forces to be restored back to greatness. To support this ministry financially, visit: https://www.oneplace.com/donate/707/29

“And it feels good because when I left the job, I really kinda lost my identity for a while, and I felt like I wasn't able to help people.  And lately, especially, I've sort of gotten some of that back, where I'm giving back to the community I love so much.  I know these men and women who, you know, selflessly go out every day and sacrifice so much.” – Ret. Firefighter/EMT Keith First responders often excel at compartmentalizing the difficult aspects of their job. This may serve as an effective temporary coping mechanism, but the mounting pressure of complex, unprocessed trauma can lead to a deluge of feelings and thoughts that seem insurmountable. While that tipping point varies for everyone, for Keith, it took 17 years and a reunion with one of his colleagues to truly realize the power that one of the worst calls of his career had held over him for all those years. Join former firefighter/paramedic and host Phil Klein as he sits down with retired firefighter and EMT, Keith. Just 18 years old when he joined the fire department, Keith recalls being prepared to see difficult situations but unprepared to deal with the individual and cumulative impact those events would have on his mental health and his life. Now, Keith helps those who are new to or are considering a career as a first responder understand how to break the stigma around asking for help and better prepare for the mental and emotional tolls of public service.Thank you for listening to Stories From the Road! To learn more about the advocacy work Keith is doing for first responders affected by PTSD, please take a moment to check out these links:·        The Sunday Group·        First Responder Coaching·        Keith's YouTube ChannelSupport the show

On today's episode, Dennis speaks with 12 year law enforcement Vet, Invicta FC pro-fighter and founder of OTX Tactics, Ashley "Smashley" Cummins and Ret. Army Ranger, SWAT officer & Founder & CEO of We Go Home, Trung Nguyen. The gang discuss the ups and downs of business and entrepreneurship, importance of self-educating with books and podcasts, how to be successful in business and ignoring the noise and focusing on the work. Check out OTX Tactics: https://www.facebook.com/OTXtactics Check out WE GO HOME: https://wegohomesupps.com If you like what you are hearing and want to stay in the loop with the latest in Street Cop Training, please follow our Facebook Page: https://www.facebook.com/StreetCopTraining Don't forget to subscribe and rate the podcast, it truly helps! Sign up for classes here: https://streetcoptraining.com/course-list/Follow our podcast here: https://streetcoptraining.com/street-cop-podcast/ or https://podcasts.apple.com/us/podcast/street-cop-podcast/id1538474515

Ret. Army Major General Joe Arbuckle discusses the Flag Officers 4 America open letter that provides citizens with a national security assessment and asks citizens to get involved and vote. Joe Brunner, local independent owner of Lukas Liquors, explains that a "NO" vote on the three ballot alcohol questions will ultimately preserve lower prices and choices for consumers in Colorado.

Dr. Vamsi Velcheti and Dr. Benjamin Neel, of the NYU Langone Perlmutter Cancer Center, and Dr. John Heymach, of MD Anderson Cancer Center, discuss new therapeutic approaches for KRAS-mutant lung cancers and therapy options for RAS-altered tumors.   TRANSCRIPT Dr. Vamsidhar Velcheti: Hello, I'm Dr. Vamsidhar Velcheti, your guest host for the ASCO Daily News podcast today. I'm the medical director of the Thoracic Oncology Program at Perlmutter Cancer Center at NYU Langone Health. I'm delighted to welcome two internationally renowned physician-scientists, Dr. John Heymach, the chair of Thoracic-Head & Neck Medical Oncology at the MD Anderson Cancer Center, and my colleague, Dr. Benjamin Neel, the director of the Perlmutter Cancer Center at NYU Langone Health, and professor of Medicine at NYU Grossman School of Medicine. So, we'll be discussing new therapeutic approaches today for KRAS-mutant lung cancers, and we will talk about emerging new targeted therapy options for RAS-altered tumors. Our full disclosures are available in the show notes, and the disclosures of all the guests of the podcast can be found on our transcript at: asco.org/podcast. Dr. Heymach and Dr. Neel, it's such a great pleasure to have you here for the podcast today. Dr. John Heymach: My pleasure to be here. Dr. Benjamin Neel: Same here. Dr. Vamsidhar Velcheti: Dr. Neel, let's start off with you. As you know, RAS oncogenes were first discovered nearly four decades ago. Why is RAS such a challenging therapeutic target? Why has it taken so long to develop therapeutic options for these patients? Dr. Benjamin Neel: Well, I think a good analogy is the difference between kinase inhibitors and RAS inhibitors. So, kinase inhibitors basically took advantage of an ATP-binding pocket that's present in all kinases, but is different from kinase to kinase, and can be accessed by small molecule inhibitors. So, the standard approach that one would've thought of taking, would be to go after the GTP-binding pocket. The only problem is that the affinity for binding GTP by KRAS is three to four orders of magnitude higher. So, actually getting inhibitors that are GTP-binding inhibitors is pretty much very difficult. And then, until recently, it was felt that RAS was a very flat molecule and there weren't any surfaces that you could stick a small molecule inhibitor in. So, from a variety of biochemical and medicinal-pharmacological reasons, RAS was thought to be impervious to small molecule development. But as is often the case, a singular and seminal insight from a scientist, Kevan Shokat, really broke the field open, and now there's a whole host of new approaches to trying to drug RAS. Dr. Vamsidhar Velcheti: So, Dr. Neel, can you describe those recent advances in drug design that have enabled these noble new treatments for KRAS-targeted therapies? Dr. Benjamin Neel: So, it starts actually with the recognition that for many years, people were going after the wrong RAS. And by the wrong RAS, the overwhelming majority of the earlier studies on the structure, and for that matter, the function of RAS centered on HRAS or Harvey RAS. We just mutated in some cancers, most prominently, bladder cancer, and head & neck cancer, but not on KRAS, which is the really major player in terms of oncogenes in human cancer. So, first of all, we were studying the wrong RAS. The second thing is that we were sort of thinking that all RAS mutants were the same. And even from the earliest days, back in the late eighties, it was pretty clear that there were different biochemical properties in all different RAS mutants. But this sort of got lost in the cause and in the intervening time, and as a result, people thought all RASes were the same and they were just studying mainly G12V and G12D, which are more difficult to drug. And then, the third and most fundamental insight was the idea of trying to take advantage of a particular mutation in KRAS, which is present in a large fraction of lung cancer patients, which is, KRAS G12C. So, that's a mutation of glycine 12 to cysteine and Kevan's really seminal study was to use a library of covalently adducting drugs, and try to find ways to tether a small molecule in close enough so that it could hit the cysteine. And what was really surprising was when they actually found the earliest hits with this strategy, which was actually based on some early work by Jim Wells at Sunesis in the early part of this century, they found that it was actually occupying the G12C state or the inactive state of RAS. And this actually hearkens back to what I said earlier about all RASes being the same. And in fact, what's been recently re-appreciated is that some RAS mutants, most notably, G12C, although they're impervious to the gap which converts the active form into the inactive form, they still have a certain amount of intrinsic ability to convert from the inactive form. And so, they always cycle into the inactive form at some slow rate, and that allows them to be accessed by these small molecules in the so-called Switch-II Pocket, and that enables them to position a warhead close enough to the cysteine residue to make a covalent adduct and inactivate the protein irreversibly. Scientists at a large number of pharmaceutical companies and also academic labs began to understand how to access various other pockets in RAS, and also even new strategies, taking advantage of presenting molecules to RAS on a chaperone protein. So, there's now a whole host of strategies; you have a sort of an embarrassment of riches from an impoverished environment that we started with prior to 2012. Dr. Vamsidhar Velcheti: Thank you, Dr. Neel. So, Dr. Heymach, lung cancer has been a poster child for personalized therapy, and we've had like a lot of FDA-approved agents for several molecularly-defined subsets of lung cancer. How clinically impactful is a recent approval of Sotoracib for patients with metastatic lung cancer? Dr. John Heymach: Yeah. Well, I don't think it's an exaggeration to say this is the biggest advance for targeted therapies for lung cancer since the initial discovery of EGFR inhibitors. And let me talk about that in a little more detail. You know, the way that lung cancer therapy, like a lot of other cancer therapies, has advanced is by targeting specific driver oncogenes. And as Dr. Neel mentioned before, tyrosine kinases are a large percentage of those oncogenes and we've gotten very good at targeting tyrosine kinases developing inhibitors. They all sort of fit into the same ATP pocket, or at least the vast majority of them now. There are some variations on that idea now like allosteric inhibitors. And so, the field has just got better and better. And so, for lung cancer, the field evolved from EGFR to ALK, to ROS1 RET fusions, MEK, and so forth. What they all have in common is, they're all tyrosine kinases. But the biggest oncogene, and it's about twice as big as EGFR mutation, are KRAS mutations. And as you mentioned, this isn't a tyrosine kinase. We never had an inhibitor. And the first one to show that it's targetable, to have the first drug that does this, is really such an important breakthrough. Because once the big breakthrough and the concept is there, the pharmaceutical companies in the field can be really good at improving and modulating that. And that's exactly what we see. So, from that original insight that led to the design of the first G12C inhibitors, now there's dozens, literally dozens of G12C inhibitors and all these other inhibitors based on similar concepts. So, the first one now to go into the clinic and be FDA-approved is Sotoracib. So, this again, as you've heard, is inhibitor G12C, and it's what we call an irreversible inhibitor. So, it fits into this pocket, and it covalently links with G12C. So, when it's linked, it's linked, it's not coming off. Now, the study that led to its FDA approval was called the CodeBreak 100 study. And this was led in part, by my colleague Ferdinandos Skoulidis, and was published in The New England Journal in the past year. And, you know, there they studied 126 patients, and I'll keep just a brief summary, these were all refractory lung cancer patients. They either had first-line therapy, most had both chemo and immunotherapy. The primary endpoint was objective response rate. And for the study, the objective response rate was 37%, the progression-free survival was 6.8 months, the overall survival was 12.5 months. Now you might say, well, 37%, that's not as good as an EGFR inhibitor or the others. Well, this is a much harder thing to inhibit. And you have to remember in this setting, the standard of care was docetaxel chemotherapy. And docetaxel usually has a response rate of about 10 to 13%, progression-free survival of about 3 months. So, to more than double that with a targeted drug and have a longer PFS really is a major advance. But it's clear, we've got to improve on this and I think combinations are going to be incredibly important now. There's a huge number of combination regimens now in testing. Dr. Vamsidhar Velcheti: Thank you, Dr. Heymach. So, Dr. Neel, just following up on that, unlike other targeted therapies in lung cancer, like EGFR, ALK, ROS, and RET, the G12C inhibitors appear to have somewhat modest, I mean, though, certainly better than docetaxel that Dr. Heymach was just talking about; why is it so hard to have more effective inhibitor of KRAS here? Is it due to the complex nature of RAS-mutant tumors? Or is it our approach for targeting RAS? Is it a drug-related problem, or is it the disease? Dr. Benjamin Neel: Well, the short answer is I think that's a theoretical discussion at this point and there isn't really good data to tell you, but I suspect it's a combination of those things. We'll see with the new RAS(ON) inhibitors, which seem to have deeper responses, even in animal models, if those actually work better in the clinic, then we'll know at least part of it was that we weren't hitting RAS hard enough, at least with the single agents. But I also think that it's highly likely that since KRAS-mutant tumors are enriched in smokers, and smokers have lots of mutations, that they are much more complex tumours, and therefore there's many more ways for them to escape. Dr. Vamsidhar Velcheti: Dr. Heymach, you want to weigh in on that? Dr. John Heymach: Yeah, I think that's right. I guess a couple of different ways to view it is the problem that the current inhibitors are not inhibiting the target well enough, you know, in which case we say we get better and better inhibitors will inhibit it more effectively, or maybe we're inhibiting it, but we're not shutting down all the downstream pathways or the feedback pathways that get turned on in response, in which case the path forward is going to be better combinations. Right now, I think the jury is still out, but I think the data supports that we can do better with better inhibitors, there's room to grow. But it is also going to be really important hitting these compensatory pathways that get turned on. I think it's going to be both, and it seems like KRAS may turn on more compensatory pathways earlier than things like EGFR or ALK2, you know, and I think it's going to be a great scientific question to figure out why that is. Dr. Vamsidhar Velcheti: Right. And just following up on that, Dr. Heymach, so, what do we know so far about primary and acquired resistance to KRAS G12C inhibitors? Dr. John Heymach: Yeah. Well, it's a great question, and we're still very early in understanding this. And here, if we decide to call it primary resistance - meaning you never respond in the first place, and acquired - meaning you respond and then become resistant, we're not sure why some tumors do respond and don't respond initially. Now, it's been known for a long time, tumors differ in what we call their KRAS-dependence. And in cell lines and in mouse models, when you study this in the lab, there are some models where if you block KRAS, those cells will die immediately. They are fully dependent. And there's other ones that become sort of independent and they don't really seem to care if you turn down KRAS, they've sort of moved on to other things they're dependent on. One way this can happen is with undergoing EMT where the cell sort of changes its dependencies. And EMT is probably a reason some of these tumors are resistant, to start with. It may also matter what else is mutated along with KRAS, what we call the co-mutations, the additional mutations that occur along with it. For example, it seems like if this gene KEAP1 is mutated, tumors don't respond as well, to begin with. Now, acquired resistance is something we are gaining some experience with. I can say in the beginning, we all knew there'd be resistance, we were all waiting to see it, and what we were really hoping for was the case like with first-generation inhibitors with EGFR, where there was one dominant mechanism. In the first-generation EGFR, we had one mutation; T790M, that was more than half the resistance. And then we could develop drugs for that. But unfortunately, that's not the case. It looks like the resistance mechanisms are very diverse, and lots of different pathways can get turned on. So, for acquired resistance, you can have additional KRAS mutations, like you can have a KRAS G12D or V, or some other allele, or G13, I didn't even realize were commonly mutated, like H95 or Y96 can get mutated as well. So, we might be able to inhibit with better inhibitors. But the more pressing problem is what we call bypass; when these other pathways get turned on. And for bypass, we know that the tumor can turn on MET with MET amplification, NRAS, BRAF, MAP kinase, and we just see a wide variety. So, it's clear to us there isn't going to be a single easy to target solution like there was for EGFR. This is going to be a long-term problem, and we're going to have to work on a lot of different solutions and get smarter about what we're doing. Dr. Vamsidhar Velcheti: Yeah. Thank you very much, Dr. Heymach. And Dr. Neel, just following up on that, so, what do you think our strategies should be or should look like while targeting KRAS-mutant tumors? Like, do we focus on better ways to inhibit RAS, or do we focus on personalized combination approaches based on various alterations or other biomarkers? Dr. Benjamin Neel: Yeah. Well, I'd like to step back a second and be provocative, and say that we've been doing targeted therapies, so to speak, for a long time, and it's absolutely clear that targeted therapies never cure. And so, I think we should ask the bigger question, "Why is it that targeted therapies never cure?" And I would start to conceive of an answer to that question by asking which therapies do cure. And the therapies that we know do cure are immune therapies, or it's therapies that generate durable immune response against the tumor. And the other therapies that we know that are therapies in some cases against some tumors, and radiation therapy in some cases against some tumors. Probably the only way that those actually converge on the first mechanism I said that cures tumors, which is generating a durable immune response. And so, the only way, in my view, it is to durably cure an evolving disease, like a cancer, is to have an army that can fight an evolving disease. And the only army I know of is the immune system. So, I think ultimately, what we need to do is understand in detail, how all of these different mutations that lead to cancer affect immune response and create targetable lesions in the immune response, and then how the drugs we'd give affect that. So, in the big picture, the 50,000-foot picture, that what we really need to spend more attention on, is understanding how the drugs we give and the mutations that are there in the first place affect immune response against the tumor, and ultimately try to develop strategies that somehow pick up an immune response against the tumor. Now in the short run, I think there's also lots of combination strategies that we can think of, John, you know, alluded to some of them earlier. I mean one way for the G12C inhibitors, getting better occupancy of the drug, and also blocking this so-called phenomenon of adaptive resistance, where you derepress the expression of receptor tyrosine kinases, and their ligands, and therefore bypass through normal RAS or upregulate G12C into the GTP state more, that can be attacked by combining, for example, with the SHIP2 inhibitor or a SOS inhibitor. Again, the issue there will be therapeutic index. Can we achieve that with a reasonable therapeutic index? Also in some cases, like not so much in lung cancer, but in colon cancer, it appears as if a single dominant receptor tyrosine kinase pathway, the EGF receptor pathway, is often the mechanism of adaptive resistance to RAS inhibitors, and so, combining a RAS inhibitor with an EGF receptor inhibitor is a reasonable strategy. And then of course, some of the strategies they're already getting at, what I just mentioned before, which is to try to combine RAS inhibitors with checkpoint inhibitors. I think that's an expected and understandable approach, but I think we need to get a lot more sophisticated about the tumor microenvironment, and how that's affecting the immune response. And it's not just going to be, you know, in most cases combining with a checkpoint inhibitor. I think we ought to stop using the term immunotherapy to refer to checkpoint inhibitors. Checkpoint inhibitors are one type of immunotherapy. We don't refer to antibiotics when we mean penicillin. Dr. Vamsidhar Velcheti: Dr. Heymach, as you know, like, there's a lot of discussion about the role of KRAS G12C inhibitors in the frontline setting. Do you envision these drugs are going to be positioning themselves in the frontline setting as a combination, or like as a single agent? Are there like a subset of patients perhaps where you would consider like a single agent up front? Dr. John Heymach: So, I think there's no question G12C inhibitors are moving to the first-line question. And the question is just how you get there. Now, the simplest and most straightforward approach is to say, “Well, we'll take our standard and one standard might be immunotherapy alone, a PD-1 inhibitor alone, or chemo with the PD-1 inhibitor, and just take the G12C inhibitor and put it right on top.” And that's a classic strategy that's followed. That may not be that simple. It's not obvious that these drugs will always work well together or will be tolerated together. So, I think that's still being worked out. Now, an alternative strategy is you could say, “Well, let's get a foot in a door in the first-line setting by finding where chemotherapy and immunotherapy don't work well, and pick that little subgroup.” There are some studies there using STK11-mutant tumors, and they don't respond well to immunotherapy and chemotherapy and say, “Well, let's pick that first.” And that's another strategy, but that's not to get it for everybody in the first-line setting. That's just to pick a little subgroup. Or we may develop KRAS G12C inhibitor combinations by themselves that are so effective they can beat the standard. So, what I think is going to happen is a couple things; I think they'll first be some little niches where it gets in there first. I think eventually, we'll figure out how to combine them with chemotherapy and immunotherapy so it goes on top. And then I think over time, we'll eventually develop just more effective, targeted combos where we can phase out the chemo, where the chemo goes to the back of the line, and this goes to the front of the line. Dr. Vamsidhar Velcheti: And Dr. Heymach, any thoughts on the perioperative setting and the adjuvant/neoadjuvant setting, do you think there's any role for these inhibitors in the future? Dr. John Heymach: Yeah, this is a really exciting space right now. And so that makes this a really challenging question because of how quickly things are moving. I'll just briefly recap for everybody. Until recently, adjuvant therapy was just chemotherapy after you resected a lung cancer. That was it. And it provided about a 5% benefit in terms of five-year disease-free survival. Well, then we had adjuvant immunotherapy, like atezolizumab, approved, then we had neoadjuvant chemo plus immunotherapy approved; that's a CheckMate 816. And just recently, the AEGEAN study, which I'm involved with, was announced to be a positive study. That's neoadjuvant plus adjuvant chemo plus immunotherapy. So now, if you say, well, how are you going to bring a G12C inhibitor in there? Well, you can envision a few different ways; if you can combine with chemo and immunotherapy, you could bring it up front and bring it afterwards, or you could just tack it in on the back, either with immunotherapy or by itself, if you gave neoadjuvant chemo plus immunotherapy first, what we call the CheckMate 816 regimen. So, it could fit in a variety of ways. I'll just say neoadjuvant is more appealing because you can measure the response and see how well it's working, and we in fact have a neoadjuvant study going. But the long-term benefit may really come from keeping the drug going afterwards to suppress microscopic metastatic disease. And that's what I believe is going to happen. I think you're going to need to stay on these drugs for a long while to keep that microscopic disease down. Dr. Vamsidhar Velcheti: Dr. Neel, any thoughts on novel agents in development beyond KRAS G12C inhibitors? Are there any agents or combinations that you'd be excited about? Dr. Benjamin Neel: Well, I think that the YAP/TAZ pathway inhibitors, the TEAD inhibitors in particular, are potentially promising. I mean, it seems as if the MAP kinase pathway and the GAPT pathway act in parallel. There's been multiple phases which suggest that YAP/TAZ reactivation can be a mechanism of sort of state-switching resistance. And so, I think those inhibitors are different than the standard PI3 kinase pathway inhibitor, PI3 kinase mTOR inhibitor, rapamycin. I also think as we've alluded to a couple of times, the jury's still out in the clinic, of course, but it'll be very exciting to see how this new set of RAS inhibitors works. The sort of Pan-RAS inhibitors, especially the ones that hit the GTP ON state. So, the G12C inhibitors and the initial preclinical G12D inhibitors that have been recorded, they all work by targeting the inactive state of RAS, the RAS-GDP state. And so, they can only work on mutants that cycle, at least somewhat, and they also don't seem to be as potent as targeting the GTP or active state of RAS. And so, at least the Rev meds compounds, which basically use cyclophilin, they basically adapt the mechanism that cyclosporine uses to inhibit calcineurin. They basically use the same kind of a strategy and build new drugs then that bind cyclophilin and present the drug in a way that can inhibit multiple forms of RAS. So, it'll be interesting to see if they are much more efficacious in a clinic as they appear to be in the lab, whether they can be tolerated. So, I think those are things to look out for. Dr. Vamsidhar Velcheti: Dr. Heymach? Dr. John Heymach: Yeah, I agree with that. I'm excited to see that set of compounds coming along. One of the interesting observations is that when you inhibit one KRAS allele like G12C, you get these other KRAS alleles commonly popping up. And it's a little -- I just want to pause for a second to comment on this, because this is a little different than EGFR. If you inhibit a classic mutation, you don't get multiple other separate EGFR alleles popping up. You may get a secondary mutation in cyst on the same protein, but you don't get other alleles. So, this is a little different biology, but I think the frequency that we're seeing all these other KRAS alleles pop up tells us, I think we're going to need some pan-KRAS type strategy as a partner for targeting the primary driver. So for example, a G12C inhibitor plus a pan-KRAS strategy to head off these other alleles that can be popping up. So, I think that's going to be probably a minimum building block that you start putting other things around. And by partnering an allele-specific inhibitor where you might be able to inhibit it a little more potently and irreversibly with a pan-KRAS, you may solve some of these problems at the therapeutic window. You can imagine KRAS is so important for so many different cells in your body that if you potently inhibit all KRAS in your body, bad things are likely to happen somewhere. But if you can potently inhibit the mutant allele and then dampen the other KRAS signaling that's popping up, it's more hopeful. Dr. Benjamin Neel: There is a mouse model study from Mariano Barbacid's lab, which suggests that postnatal, KRAS at least, complete inhibition is doable. So, you could take out KRAS postnatally and the mice are okay. Whether that translates to human of course, is not at all clear. And you still have the other RAS alleles, the HRAS, the NRAS that you'd still have to contend with. Dr. John Heymach: Yeah, it's an interesting lesson. We've shied away from a lot of targets we thought weren't feasible. I did a lot of my training with Judah Folkman who pioneered targeting angiogenesis. And I remember hearing this idea of blocking new blood vessels. I said, "Well, everyone is just going to have a heart attack and die." And it turns out you can do it. You have to do it carefully, and in the right way but you can separate malignant or oncogenic signaling from normal signaling in an adult, pretty reasonably in a lot of cases where you don't think you could. Dr. Vamsidhar Velcheti: All right. So, Dr. Neel, and Dr. Heymach, any final closing comments on the field of RAS-targeted therapies, you know, what can we hope for? What can patients hope for, let's say five years from now, what are we looking at? Dr. John Heymach: Well, I'll give my thoughts I guess first, from a clinical perspective, I think we're already seeing the outlines of an absolute explosion in targeting KRAS over the next five years. And I think there's a really good likelihood that this is going to be the major place where we see progress, at least in lung cancer, over these next five years. It's an example of a problem that just seemed insolvable for so long, and here I really want to acknowledge the sustained support for clinical research and laboratory research focused around RAS. You know, the NCI had specific RAS initiatives and we've had big team grants for KRAS, and it shows you it's worth these large-scale efforts because you never know when that breakthrough is going to happen. But sometimes it just takes, you know, opening that door a little bit and everybody can start rushing through. Well, I think for KRAS, the door has been opened and everybody is rushing through at a frantic rate right now. So, it's really exciting, and stay tuned. I think the landscape of RAS-targeting is going to look completely different five years from now. Dr. Benjamin Neel: So, I agree that the landscape will definitely look different five years from now, because it's reflective of stuff that's been in process for the last five years. And it takes about that long to come through. I want to make two comments; one of which is to slightly disagree with my friend, John, about these big initiatives. And I would point out that this RAS breakthrough did not come from a big initiative, it came from one scientist thinking about a problem uniquely in a different way. We need a basic science breakthrough, it almost always comes from a single lab person, thinking about a problem, often in isolation, in his own group. What big initiatives can help with is engineering problems. Once you've opened the door, and you want to know what the best way is to get around the house, then maybe big initiatives help. But I do think that there's been too much focus on the big team initiative and not enough on the individual scientists who often promote the breakthrough. And then in terms of where I see the field going, what I'd really like to see, and I think in some pharmaceutical companies and biotechs, you're seeing this now, and also in academia, but maybe not enough, is that sort of breaking down of the silos between immunotherapy and targeting therapy. Because I agree with what John said, is that targeted therapy, is just sophisticated debulking. If we want to really make progress-- and on the other hand, immunotherapy people don't seem to, you know, often recognize that these oncogenic mutations in the tumor actually affect the immune system. So, I think what we need is a unification of these two semi-disparate areas of therapeutics in a more fulsome haul and that will advance things much quicker. Dr. Vamsidhar Velcheti: Thank you both, Dr. Neel and Dr. Heymach, for sharing all your valuable insights with us today on the ASCO Daily News podcast. We really appreciate it. Thank you so much. Dr. John Heymach: Thanks for asking us. Dr. Benjamin Neel: It's been great having us. Dr. Vamsidhar Velcheti: And thank you all to our listeners, and thanks for joining us today. If you value our insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Vamsi Velcheti @VamsiVelcheti Dr. Benjamin Neel @DrBenNeel Dr. John Heymach Want more related content? Listen to our podcast on novel therapies in lung cancer.    Advances in Lung Cancer at ASCO 2022 Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Vamsi Velcheti: Honoraria: Honoraria Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline Dr. Benjamin Neel: None disclosed Dr. John Heymach: None disclosed    

North Korea launched 23 missiles as a show of force. South Korea responded in kind. China is objecting to the U.S. basing B-52 bombers in Australia. We know China wants to takeover Taiwan. Will the U.S. get into a war in Asia? Lt. Col. (Ret.) Tony Shaffer, President of the London Center for Policy Research, joins the show. The Rick Roberts Show is on NewsTalk 820 WBAP ... (Photo Courtesy of WFAA)See omnystudio.com/listener for privacy information.

Daniel Hoffman, Ret. CIA Senior Clandestine Services Officer and a Fox News Contributor Topic: Vladimir Putin's stance on TaiwanHilary Kramer, One of Wall Street's most successful equity analysts & investment managersTopic: Elon Musk's purchase of Twitter and its impact on the stock marketJim McLaughlin, pollster, strategic consultant, and CEO and Partner of McLaughlin & Associates Topic: Midterm pollingSee omnystudio.com/listener for privacy information.

Benjamin Ordiway, former 92 CA and now a philosophy instructor at US military academy interviews Dr. C. Anthony Pfaff (Colonel, U.S. Army, Ret.), who is currently the research professor for Strategy, the Military Profession and Ethics at the Strategic Studies Institute and a Senior Non-Resident Fellow at the Atlantic Council.  Dr. Pfaff has published "Proxy War Ethics" by the Journal of National Security Law and Policy, Military Ethics below the Threshold of War, in Parameters (Vol 50, No. 3), "The Ethics of Acquiring Disruptive Military Technologies," in the Texas National Security Review (Vol. 3, No. 1), "Western and Chinese Ways of War and their Ethics," in Parameters (Vol. 52, No. 1), "The Future of US-Iraq Relations," by the Atlantic Council. In this episode, Benjamin Ordiway guest hosts and interviews Dr. Pfaff on SOF forces and ethics. Stay tuned.  The One CA Podcast is a production of the Civil Affairs Association: https://www.civilaffairsassoc.org Sponsorship links: Tesla Government: https://teslagov.com  LC38 Brand: https://lc38brand.com Third Order Effects: https://www.thirdordereffects.com 

Featuring a discussion on recent advances in the care of patients with RET-rearranged non-small cell lung cancer with Dr Justin Gainor, moderated by Dr Neil Love.

Dr. Darrin Porcher, Retired NYPD Lieutenant, Criminal Justice Professor at Pace University and a former Army OfficerTopic: 4 thousand cops expected to leave the NYPD by the end of the yearDaniel Hoffman, Ret. CIA Senior Clandestine Services Officer and a Fox News ContributorTopic: Intel on Vladimir Putin's healthSee omnystudio.com/listener for privacy information.

On this episode, Misha speaks with Middle East expert Nicole Robinson who expounds on how MENA countries have responded to Russia's War in Ukraine and the reasons why. Ms. Robinson sheds some light on the future of the region as the conflict evolves and Russia's capacity to arm and feed its regional allies dwindles. Furthermore, she suggests that Russia's declining influence may allow for other actors to increase their influence in the Middle East region -- actors such as China, for example, which is one of the biggest recipients of oil and natural gas from the Persian Gulf. Ms. Robinson says it's unwise for the US to take a step back in the Middle East when it is geographically and strategically the region that is situated in between giants. This war is not only shifting great power competition, but also changing "how each of these countries think about their bilateral relationships." For more on Russia's War in Syria, listen to Ret. Col. Robert E. Hamilton's episode here: https://www.slavxradio.com/hamilton ABOUT THE GUEST https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQaNutVpZT13oUm_Eu8AovNN5d727uuySIXzA&usqp=CAU Nicole Robinson is a senior research associate in the Douglas and Sarah Allison Center for Foreign Policy at The Heritage Foundation, focusing on Middle East Policy. She researches and writes on economic, security, and political challenges facing the Middle East and North Africa, with a particular focus on the Levant region. Among other topics, she has written on women's empowerment and domestic developments in Iran, Lebanon, and Yemen. Before joining Heritage, Nicole lived in Jordan for a year and half, studying at the University of Jordan and working at the Stabilisation Network and Near East Foundation.She is fluent in Arabic and is continuing to expand her knowledge about the Middle East. Nicole received her Master's Degree in Arab Studies from Georgetown University's School of Foreign Service and holds a Bachelor's Degree in Middle East Studies from the University of Minnesota-Twin Cities. She was born and raised in Woodbury, Minnesota, and currently resides in Alexandria, Virginia. PRODUCER'S NOTE: This episode was recorded on October 21st, 2022 via Zoom. If you have questions, comments, or would like to be a guest on the show, please email slavxradio@utexas.edu and we will be in touch! CREDITS Assistant Producer/Host: Misha Simanovskyy (@MSimanovskyy) Associate Producer: Lera Toropin (@earlportion) Associate Producer: Cullan Bendig (@cullanwithana) Assistant Producer: Sergio Glajar Assistant Producer: Taylor Ham Social Media Manager: Eliza Fisher Supervising Producer: Katherine Birch Recording, Editing, and Sound Design: Michelle Daniel Music Producer: Charlie Harper (@charlieharpermusic) www.charlieharpermusic.com (Main Theme by Charlie Harper and additional background music by Broke For Free, Shaolin Dub, "Karma" by Kazka) Executive Producer & Creator: Michelle Daniel (@MSDaniel) www.msdaniel.com DISCLAIMER: Texas Podcast Network is brought to you by The University of Texas at Austin. Podcasts are produced by faculty members and staffers at UT Austin who work with University Communications to craft content that adheres to journalistic best practices. The University of Texas at Austin offers these podcasts at no charge. Podcasts appearing on the network and this webpage represent the views of the hosts, not of The University of Texas at Austin. https://files.fireside.fm/file/fireside-uploads/images/9/9a59b135-7876-4254-b600-3839b3aa3ab1/P1EKcswq.png Special Guest: Nicole Robinson.

Featuring an interview with Dr Justin Gainor, including the following topics: Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00) Significance of non-fusion RET abnormalities in NSCLC (3:33) Clinical impact of tumor-agnostic targeted therapy (5:11) Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46) Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24) Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45) Adjuvant therapy for RET-rearranged NSCLC (26:23) Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07) Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40) Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28) CME information and select publications

Dr Justin Gainor from Massachusetts General Hospital in Boston, Massachusetts, discusses recent therapeutic advances in non-small cell lung cancer with RET fusions. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRETNSCLC22).

What You Need to Know is President Biden is a fascist authoritarian. He reminds us of Hitler — I am not joking. The reason this is true? His almost two years as president show he views people as property of the state. The Trump Derangement Crazies liked to run this Hitler comparison, but finally we have one that make sense. It's not crazy because we can list all the ways this comparison is true. Ret. ​​Col. John Mills, national security pro, talks about his new book — The Nation Will Follow: First-hand experiences fighting the Deep State and the Action Plan for the American Citizen. John explains the great battle showdown and the battle to save the republic. Be sure to check out his website — TheNationWillFollow.com. Jonathan Gilliam, former US Navy SEAL, FBI Special, Host of The EXPERTS podcast, author & speaker, shares his book — Sheep No More: The Art of Awareness and Attack Survival. Be sure to check out his website JonathanTGilliam.com and purchase a copy of his book. Wrap up: John Fetterman is not physically ready to be in office. This just proves that Democrats really do not care about people. Another example of this is President Biden. We have to ask ourselves, who's really driving America?See omnystudio.com/listener for privacy information.

JONATHAN EMORD, A Constitutional law attorney and author of The Authoritarians: Their Assault on Individual Liberty, the Constitution, and Free Enterprise from the 19th Century to the Present (2021) An updated CDC ruling regarding the COVID-19 vaccine How this power grab is characteristic of the "deep state" The "greatest betrayal" of the United States in recent history COL. (RET.) JOHN MILLS, Senior Fellow, Center for Security Policy, Member, Committee on the Present Danger: China The importance of local county elections in the U.S. Is polling software vulnerable to hacking? What can the U.S. do to prevent voter fraud? KEVIN FREEMAN, Host, Economic War Room, Senior Fellow, Center for Security Policy, Author, “Game Plan: How to Protect Yourself from the Coming Cyber-Economic Attack” and “Secret Weapon: How Economic Terrorism Brought Down the U.S. Stock Market and Why It Can Happen Again,” Founder, Globaleconomiwarfare.com, @SecretWeaponUSA: Continued attacks on the U.S. as being "the most racist" country in the world The need to emphasize traditional American values Economic warfare taking place around the world

On today's episode, Dennis speaks with Ret. Army Ranger, SWAT officer & Founder & CEO of We Go Home, Trung Nguyen. After moving to Chicago at 3 years old from Vietnam, Trung became an Army Ranger, SWAT officer and is currently the founder of We Go Home (@wegohome). Trung talks about the struggles of growing up in the ghetto of Chicago and how him and his family made it through those tough times. He also talks about the importance of defining yourself, being clear on your mission and being the best version of yourself everyday. We Go Home is a movement and community built for all the brave souls that protect our precious freedoms.Check out WE GO HOME: https://wegohomesupps.com If you like what you are hearing and want to stay in the loop with the latest in Street Cop Training, please follow our Facebook Page: https://www.facebook.com/StreetCopTraining We apologies for the poor audio, we ran into some technical difficulties with the microphones. Don't forget to subscribe and rate the podcast, it truly helps! Sign up for classes here: https://streetcoptraining.com/course-list/Follow our podcast here: https://streetcoptraining.com/street-cop-podcast/ or https://podcasts.apple.com/us/podcast/street-cop-podcast/id1538474515

Relevant Links Show Notes | Spearing.co Jeremy Stalnecker's Website Mighty Oaks Foundation Programs Mighty Oaks Foundation March or Die with Jeremy Stalnecker The Situation Report with Chad Robichaux and Jeremy Stalnecker Jeremy Stalnecker on Instagram Jeremy Stalnecker on Twitter Jeremy Stalnecker on Facebook Jeremy Stalnecker on Youtube Lt. Gen. (Ret.) William G. Boykin | Family Research Council David Goggins Never Surrender: A Soldier's Journey to the Crossroads of Faith and Freedom, LTG (Ret.) William G. Boykin Extreme Ownership: How U.S. Navy SEALs Lead and Win, Jocko Willink and Leif Babin Discipline Equals Freedom: Field Manual Mk1-MOD1, Jocko Willink Recommended Episodes Masculine Discipleship and Freedom from Porn with Ray de la Nuez | Life on Target Podcast 099: Jeremy Stalnecker On Resiliency, Courage & Finding Balance | The Fire You Carry Jeremy Stalnecker | Dead Men Walking Podcast 03XX Series Interview: Jeremy Stalnecker, Tony Vivaldi, and Bill Kawczynski Follow Nathan Instagram LinkedIn Twitter Gab Website

Intel's Darren Pulsipher and Ret. Lt. General Thomas Horlander talk about national security, the CHIPS Act, and how securing our microelectronics supply chain is critical for everyday life and our national security. Blog: https://www.intel.com/content/www/us/en/government/podcasts/embracing-digital-transformation-episode110.html Video: https://youtu.be/zxcRt7vv7LE

Tom Del Beccaro, acclaimed author, speaker and the former Chairman of the California Republican Party Topic: San Francisco residents arming themselves with batsDaniel Hoffman, Ret. CIA Senior Clandestine Services Officer and a Fox News Contributor Topic: Putin declares martial law, China hiring British Royal Air Force pilotsPaul DeGroot, Republican running for New Jersey's 11th Congressional DistrictTopic: His campaignSee omnystudio.com/listener for privacy information.

What You Need to Know is China is hooking the US on two drugs: fentanyl and digital fentanyl (aka TikTok). Both of these are attacks on American sovereignty, and they must be addressed immediately! China is on the path to dominate their neighbors and continue to damage America. President Trump was fearless in standing up to them and also some credit where it's due to the CHIPS and Science Act of 2022 for decoupling from China as well. They're noticing! Check out this tweet: No restriction will stop China's sci-tech from advancing.  Ret. ​​Col. John Mills, national security pro, talks about his new book — The Nation Will Follow: First-hand experiences fighting the Deep State and the Action Plan for the American Citizen. John explains the great battle showdown and the battle to save the republic. Be sure to check out his website — TheNationWillFollow.com. Trish Gardner, Wreaths Across America location coordinator, talks about Wreaths Across America's Mobile Education Exhibit National Tour Makes Stops in Missouri to Honor Veterans and Supporters. Trish explains how you can see these mobile exhibits on their website — WreathsAcrossAmerica.org. Wrap up: Kanye West is learning how to keep his free speech and to help others keep theirs too!See omnystudio.com/listener for privacy information.

Nelson C. Johnson is an author, former judge, lawyer, and historian, best known for his 2002 New York Times bestseller, Boardwalk Empire. His book served as the basis for the popular and Emmy Award-winning HBO crime drama TV series, Boardwalk Empire. The Honorable Nelson C. Johnson, J.S.C.(Ret.) practiced law for 31 years prior to being appointed to the New Jersey Superior Court (Martindale-Hubbell lawyer rating: “A-V”). During his first eight years on the bench, Judge Johnson sat in the Civil Division and presided over more than 250 jury trials. During his final five years on the bench, he was one of three judges in New Jersey assigned to Multi-County Litigation, involving product liability claims. Judge Johnson recently released his new novel, - Darrow's Nightmare. Hoerner Law: https://hoernerlaw.com Cannabis Legalization in NJ: https://www.njcriminalpodcast.com/category/cannabis-legalization-nj/ Lindbergh Kidnapping Trial: https://www.njcriminalpodcast.com/category/lindbergh-kidnapping/ Lindbergh Kidnapping Blog Posts: https://www.njcriminalpodcast.com/blog/category/lindbergh-kidnapping/ Start a Legal Podcast: https://lawfirmpodcasts.com Start a Niche Business Podcast: https://nichepodcast.net

For the first time since the report has been issued, the Heritage Foundation's 2023 Index of U.S. Military Strength has issued a grade of 'weak' and describes it at a point of not being able to 'defend our national interests.' Some reasons for the grade are the increasing recruitment problems, budget cuts and even inflation. FOX's Jeff Monosso speaks with Ret. Lt. Col Dakota Wood, senior research fellow for the Heritage Foundation's Defense Programs, about the report's findings, some of the root causes and how we can change the current situation.  Click Here To Follow 'The FOX News Rundown: Evening Edition' https://listen.foxaud.io/rundown?sid=fnr.podeve  Learn more about your ad choices. Visit megaphone.fm/adchoices

Kevin Hern, U.S. Representative from the 1st District of Oklahoma, comments on President Biden's attempts to downplay the impact of record inflation and fears of a coming recession. Bob Good, U.S. Representative for the 5th District of Virginia, reacts to news that a Virginia state delegate is backing off the plan to introduce a bill criminalizing parents who don't affirm their child's gender identity. Dr. Andrew Bostom, epidemiologist, reacts to a Pfizer executive's admission that mRNA vaccines, like the COVID vaccine, were not tested for virus transmissibility. Lt. Gen. (Ret.) Jerry Boykin, FRC's Executive Vice President, pushes back on the Secretary of the Army's comments about wokeness in the military and offers his analysis on recent events in China and Ukraine. --- Support this podcast: https://anchor.fm/loving-liberty/support

For the first time since the report has been issued, the Heritage Foundation's 2023 Index of U.S. Military Strength has issued a grade of 'weak' and describes it at a point of not being able to 'defend our national interests.' Some reasons for the grade are the increasing recruitment problems, budget cuts and even inflation. FOX's Jeff Monosso speaks with Ret. Lt. Col Dakota Wood, senior research fellow for the Heritage Foundation's Defense Programs, about the report's findings, some of the root causes and how we can change the current situation.  Click Here To Follow 'The FOX News Rundown: Evening Edition' https://listen.foxaud.io/rundown?sid=fnr.podeve  Learn more about your ad choices. Visit megaphone.fm/adchoices

What do a rabbit named Jasper and a guy that loaded bombs in the military have in common? Douglas Berry, an up-and-coming children's book author and a 20-year retired US Air Force Veteran! After several tours in the service, Doug is now taking his book character, Jasper, on new adventures! In this episode of Jess Get Hired, we have a discussion about Doug's military career and his newfound career as an author. He shares his advice to transitioning veterans and what he learned after leaving the service. We have a conversation about his journey from handling weapons in the military to finding inspiration to write a book. Douglas Berry's books, "The Night I Spent in a People House" and "A Day at the Beach with Jasper and Friends" would make great gifts for the little ones on your list! Ahead of Veteran's Day, this conversation with Doug is one of a few spotlights on other great veteran stories: Episode 32 featured Ret. Lt. Col. Kathy Gallowitz, author of the book, " “Beyond Thank You for Your Service, The Veteran Champion Handbook for Civilians" Episode 34 featured Ret. Captain William Toti, author of the book, "From CO to CEO - A Practical Guide for Transitioning from Military to Industry Leadership Jess Get Hired Podcast is for career professionals, recruiters, and hiring managers who want to learn how to advance their careers, hire the best talent, and learn about the latest trends in the workplace. Visit www.jessgethired.com Buy Doug's book on Amazon, Walmart, Books-a-Million or wherever you buy your favorite books! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/jessgethired/message Support this podcast: https://anchor.fm/jessgethired/support

On today's program: Kevin Hern, U.S. Representative from the 1st District of Oklahoma, comments on President Biden's attempts to downplay the impact of record inflation and fears of a coming recession. Bob Good, U.S. Representative for the 5th District of Virginia, reacts to news that a Virginia state delegate is backing off the plan to introduce a bill criminalizing parents who don't affirm their child's gender identity. Dr. Andrew Bostom, epidemiologist, reacts to a Pfizer executive's admission that mRNA vaccines, like the COVID vaccine, were not tested for virus transmissibility. Lt. Gen. (Ret.) Jerry Boykin, FRC's Executive Vice President, pushes back on the Secretary of the Army's comments about wokeness in the military and offers his analysis on recent events in China and Ukraine. Episode Resources: Take the pledge to pray for America, vote this November, and stand for biblical truth. Watch the Pray Vote Stand Townhall, The Rise of the Term Christian Nationalism. Explore FRC's resources on life and human dignity. Check out The Washington Stand, FRC's outlet for news and commentary from a biblical worldview. Join Stand on the Word, FRC's two-year journey through the Bible! Connect with Tony on social media: Facebook, Twitter, Gettr, and Gab. To support this ministry financially, visit: https://www.oneplace.com/donate/1521/29

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.

Daniel Hoffman, Ret. CIA Senior Clandestine Services Officer and a Fox News ContributorTopic: U.S. airports knocked offline by cyber attacks, Russia strikes KyivJim Iuorio, managing director of TJM Institutional Services and a veteran futures and options trader Topic: JPMorgan Chase CEO warning of recessionSee omnystudio.com/listener for privacy information.

Today's Topics: What winter has in store for Russia and Ukraine. Moving migrants to NYC drives the Mayor nuts.  When the Red Wave hits the Border. 00:00 Sam's introduction for TUESDAY OCTOBER 11, 2022. 00:52– Ret. Lt. Col. James J. Carafano – Heritage –9 min – Talked about the progress made by the Russians before their forced retreat, and what effect that had on Ukraine and Russia. He listed specific examples of corruption in the Russian Military supply lines and what that did to their war efforts. And he talked about the opportunity heavy Ukraine winter will give to the Ukrainian army. 09:53  – Frank Vernuccio – Editor-in-Chief of New York Analysis & Policy – 8min – After listing off many of the ways President Biden has ruined America, Frank said it “can't get worse,” but it is. He pointed out that the Mayor of NYC is panicking because of the illegals being shipped in by Texas and Florida. In response, the Mayor proposed setting up a tent city in a parking lot. 18:08 – Jessica Colon – Republican Strategist – 12 min – Discussed her opinion that, if Republicans just go to the polls, the country will go red this year. She said with Abbott at the top of the ballot, and Mealer at the bottom, it should be easy to remember to vote red. Jessica pointed out the magnitude of Harris County in Federal Elections. Then she went on to discuss why Hispanics on the border are going red. 30:26 – CloseSee omnystudio.com/listener for privacy information.

1982 was a banner year for Sylvester Stallone. “Rocky III” is a knockout and months later he stars in “First Blood,” a lean, tough-fibered actioner that introduces John Rambo to the world. It's an acclaimed and important film; one can even posit that it's the best work Stallone has ever done. Not unlike Rambo, Chief Boatswain's Mate Jason Thompson, United States Navy, Ret. has seen the world in ways most of us can only dream about yet has witnessed things we hope to never experience. Jason joins Dennis to discuss the significance of the film and how one disoriented veteran became a Reagan-era, pop culture icon. Hosted on Acast. See acast.com/privacy for more information.

THE SCRIPTURE & SCRIPTURAL RESOURCES: Matthew 5:10-1210 Blessed are those who are persecuted because of righteousness, for theirs is the kingdom of heaven.11 “Blessed are you when people insult you, persecute you and falsely say all kinds of evil against you because of me. 12 Rejoice and be glad, because great is your reward in heaven, for in the same way they persecuted the prophets who were before you.Luke 14:31-3331 “Or suppose a king is about to go to war against another king. Won't he first sit down and consider whether he is able with ten thousand men to oppose the one coming against him with twenty thousand? 32 If he is not able, he will send a delegation while the other is still a long way off and will ask for terms of peace. 33 In the same way, those of you who do not give up everything you have cannot be my disciples.Hebrews 11:32-3432 And what more shall I say? I do not have time to tell about Gideon, Barak, Samson and Jephthah, about David and Samuel and the prophets, 33 who through faith conquered kingdoms, administered justice, and gained what was promised; who shut the mouths of lions, 34 quenched the fury of the flames, and escaped the edge of the sword; whose weakness was turned to strength; and who became powerful in battle and routed foreign armies.THE NEWS & COMMENT:The General's book on religious prosecution of Christians: Heroic Faith: Hope Amid Global PersecutionThe Family Policy Institute where LTG (Ret.) Boykin is Executive Vice-PresidentLt. Gen. (Ret.) William G. Boykin serves as Family Research Council's Executive Vice President.He was one of the original members of the U.S. Army's Delta Force. He was privileged to ultimately command these elite warriors in combat operations. Later, William Boykin commanded all the Army's Green Berets as well as the Special Warfare Center and School.In all, Lt. Gen. Boykin spent 36 years in the army, serving his last four years as the Deputy Undersecretary of Defense for Intelligence. He is an ordained minister with a passion for spreading the Gospel of Jesus Christ and encouraging Christians to become warriors in God's Kingdom.William and his wife Ashley enjoy spending time with their five children and growing number of grandchildren.

Whatever happened to the two-star General removed from National Defense University? Maj. Gen. Ret. Gregg Martin is committing his civilian career to stop the stigma associated with seeking treatment for mental health as he continues his own recovery from bipolar disease. Martin is sharing his passion for academia and leadership through writings, podcasts, and speaking engagements to inform and educate the military and civilian populations about the opportunities to best identify and assist in an individual's treatment and recovery. You will not meet a more genuine senior Army leader than Gregg Martin. Listen to his story of hope and purpose this Thursday on the GallantFew Podcast.

Whatever happened to the two-star General removed from National Defense University? Maj. Gen. Ret. Gregg Martin is committing his civilian career to stop the stigma associated with seeking treatment for mental health as he continues his own recovery from bipolar disease.  Martin is sharing his passion for academia and leadership through writings, podcasts, and speaking engagements to inform and educate the military and civilian populations about the opportunities to best identify and assist in an individual's treatment and recovery. You will not meet a more genuine senior Army leader than Gregg Martin. Listen to his story of hope and purpose this Thursday on the GallantFew Podcast.

On today's Breitbart News Daily podcast, we discuss Pres. Joe Biden's short-sighted energy policy and how it has put the U.S. in a precarious position. Gas prices are set to rise thanks to OPEC+ cutting oil production, a move we all should have seen coming. What we also saw coming is that Biden is going to try to buy votes by releasing more oil from our strategic reserves. This is offensive and should be illegal. We give you all the details. Then, some frightening election integrity news broke as well in the last couple of days and the New York Times has yet again tried to run defense for the Chinese Communist Party. We explain. Also, we give details on another left-wing super villain that I believe is a threat to our Republic - Reid Hoffman, the founder of LinkedIn is the subject of a major profile piece Alex put together for Breitbart News. Highlights of the reporting are shared on the show. Our guest today is Ret. Navy SEAL Derrick Van Orden, who is trying to flip a crucial House seat in Wisconsin. He talks about character, teamwork, the lawlessness of the Democrat party, and the importance of stopping Communist China. It's an excellent interview.

Ret. Police Chief Ken Laird explains how distrusting parents rushing into schools during locked downs is due to the Uvalde Effect.

EPISODE #795 THE RISE OF CONSERVATIVE POPULISM Richard speaks with a retired U.S. Army Chaplain and an investigative journalist about the rise of conservative populism across Europe, including the recent election of Giorgia Meloni, Italy's first female prime minister. Guest: U.S. Army Chaplain (Col.) David Giammona, Ret., President of Battle Ready Ministries, is an end-time expert, scholar, author, writer, and speaker. He and Troy Anderson wrote the number one bestselling book The Military Guide to Armageddon released January 2021 and their second book in the series, The Military Guide to Disarming Deception. Guest: Troy Anderson is a Pulitzer Prize-nominated investigative journalist, #1 bestselling FaithWords/Hachette author of The Babylon Code and Trumpocalypse, #1 bestselling Chosen Books author of The Military Guide to Armageddon, former executive editor of Charisma magazine and Charisma Media and reporter at the Los Angeles Daily News, and a frequent guest on many television and radio shows. He writes for Reuters, Newsmax, Townhall and other media outlets. He's executive editor of The Return International, vice president and COO of Battle Ready Ministries and founder and editor-in-chief of Prophecy Investigators. BOOKS: The Military Guide to Disarming Deception: Battlefield Tactics to Expose the Enemy's Lies and Triumph in Truth The Military Guide to Armageddon: Battle-Tested Strategies to Prepare Your Life and Soul for the End Times SUPPORT OUR SPONSORS!!! TRADE COFFEE - Start your day with the very best tasting coffee delivered fresh, when you need it! Receive $30 OFF your first order plus free shipping at drinktrade.com/strangeplanet BLINKIST - MORE KNOWLEDGE IN LESS TIME! Perfect for curious people who love to learn, busy people who don't have time to read, and even people who aren't into reading. Visit Blinkist.dot.com/RSSP to get 25% off and a 7-day free trial. And now for a limited time you can even use Blinkist Connect to share your premium account you will get 2 premium subscriptions for the price of one. COPY MY CRYPTO - Discover how over 1,300 people - many of who know nothing about crypto or how to invest - are building rapid wealth the cabal can never steal - "You don't need to know a thing about cryptocurrency if you copy someone who does" CopyMyCrypto.com/Dollar SUBSCRIBE TO STRANGE PLANET PREMIUM HERE: https://strangeplanet.supportingcast.fm/ Use the discount code "Planet" to receive one month off the first subscription Learn more about your ad choices. Visit megaphone.fm/adchoices We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

Ret. Sgt. (MA State Police) Billy McGreal joins us for a "deep dive" into David Clark, the man who killed Trooper Mark S. Charbonnier, and his mis-deeds prior to Sept. 2, 1994. Plus, Sgt. McGreal's relationship with Mark Rosetti and the argument for his paid informant status with the FBI from 1991-2010. 

Here are the links for everything discussed in Episode 80. Times are also below so feel free to skip around and get to the updates that interest you.  (1:14) FDA issues warning related to OTC meds & social media challenges (4:20) FDA approval of Skysona for CALD (6:07) New indication for Retevmo (7:12) FDA approves Relyvrio for ALS PAXLOVID Patient Eligibility Screening Checklist Tool for PrescribersCDC website for COVID information - get boosted!FDA monkeypox response websiteConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

What You Need to Know is the comparison from 1894 to 2022. We are in a similar situation as in 1894. They were in a recession back then. There was a problem with wheat, inflation, silver, the stock market tanked, banks closed, businesses closed, etc. Their problem was economics. What did they do? They went to the polls in 1894 and punished the party in power and that party in power was the Democrats. We are in 2022 but it's almost like 1894 again and it's time for us to go to the polls and make our voices heard! Former Senator Phil Gramm, served six years in the US House of Representatives and eighteen years in the US Senate where he was Chairman of the Banking Committee, unpacks surprising data from his brand new book — The Myth of American Inequality: How Government Biases Policy Debate. Senator Gramm has found that in the last 7 years there's been an unexpected shift in income equality - unexpected, unless you're MAGA. Buy your own copy of The Myth of American Inequality here.  Lt. Col. Stuart Scheller (USMC, Ret.), Father, American, Marine, shares his brand new book — Crisis of Command: How We Lost Trust and Confidence in America's Generals and Politicians. Scheller explains that in his book he identifies the problems with the military but he gives a path forward to get the military back on track. Purchase your own copy of Crisis of Command here.  Wrap up: Have a great weekend!See omnystudio.com/listener for privacy information.

Sodium thiosulfate is now FDA-approved to minimize the risk of ototoxicity in some children receiving cisplatin. Selpercatinib is granted a 'regular' approval for RET-fusion (+) NSCLC and an accelerated approval for other solid tumors.

Featuring an interview with Dr Heather Wakelee, including the following topics: Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00) Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15) Activity of immunotherapy in patients whose tumors are EGFR mutated (10:29) Case: A woman in her mid 70s with EGFR-mutated NSCLC in her right lung (14:49) Case: A woman in her early 60s with a smoking history and a 4-cm right lower lobe lesion (24:17) Case: A man in his mid 50s with a smoking history and a left upper lobe mass with high PD-L1 expression (28:04) Optimal treatment of localized NSCLC in patients who have alterations in RET, BRAF and ALK (33:08) Importance of primary care doctors screening their patients for lung cancer (37:03) CME information and select publications

Following the Dobbs  v. Jackson Women's Health Organization Supreme Court decision, reproductive rights are heading to ballots in states across the country this fall. Are states the right venue for this and other issues? Our guest this week says yes and makes the case that state courts and constitutions are more democratic than their counterparts at the federal level.In Who Decides? State as Laboratories of Constitutional Experimentation, U.S. Appellate Court Judge Jeffrey S. Sutton focuses on the constitutional structure of the American states to answer the question of who should decide the key questions of public policy today. We also discuss work by Jake Grumbach in his book Laboratories Against Democracy and the forthcoming Moore v. Harper case in the U.S. Supreme Court, which grapples with what's come to be known as the Independent State Legislature Theory.Sutton is the  Chief Judge of the United States Court of Appeals for the Sixth Circuit. He was previously a partner with the law firm of Jones Day and served as State Solicitor of the State of Ohio. He also served as a law clerk to the Honorable Lewis F. Powell, Jr. (Ret.), the Honorable Antonin Scalia, and the Honorable Thomas J. Meskill. His previous book is 51 Imperfect Solutions, published in 2018.Who Decides: States as Laboratories of Constitutional Experimentation

When you were 16 years old, what was your biggest fear? Not passing your drivers test, not having a date for the school dance, or maybe it was just getting through that damn chemistry class. Well, what if you were born in Syria, and at 16 yrs old, your daily routine was war, and your biggest fear was watching your friends die. And what if your reality was so dire, that you would choose to end your own life, rather than be captured and forced to experience a death most people cannot comprehend, at the hands of an evil most people can't even imagine. This is the life of the YPJ, the Women's Protection Units of Syria and their fight against ISIS. On today's episode I welcome back Ret. AF CCT MSgt Eric Ballester, who served with a team of US Army Delta Force operators as advisors to the YPJ and witnessed first hand the dedication, sacrifice, and ferocity that is manifested when a group of young Syrian girls fight for their home. Recommend you buckle up for this one. 

COL. (RET.) JOHN MILLS, Senior Fellow, Center for Security Policy, Member, Committee on the Present Danger: China Mills' role in the upcoming film Innovation Race New legislation on patent reform in the United States How is China taking advantage of the U.S. patent system? Why should we be concerned with China's role with the patent system? Mills' experience in the "swamp" in Washington, D.C.

Anthony sits down with Ret. Sgt. Manny Luciano to speak about his career in law enforcement and the military. Manny shares personal and emotional stories from his time in law enforcement and his multiple combat tours in the military. This includes a car stop with an uzi, the murder of a baby, and his military duties after the capture of Saddam Hussein. At the end of the episode Anthony addresses the 30x30 Initiative and why it is so woke it's broke. He also highlights the work of a local officer who worked through an assault and recovered multiple stolen guns during the KUtheDIP segment. Plus the story of Stephen in Acts 7 and why Jesus stands for those who confess and believe. TIME STAMPS: 05:14-Interview with Ret. Sgt. Manny Luciano 02:11:19-So Woke It's Broke Segment 02:39:38-KUtheDIP 02:43:42-Why did Jesus Stand for Stephen   Diakonos ACC Podcast Website:                   www.diakonosacc.com The Lancaster Patriot:                         www.thelancasterpatriot.com Iron Shirt BBQ Co.                                        www.facebook.com/Iron-Shirt-BBQ-Co-103465168925512 Free 30 Day Audible Trial:          www.audibletrial.com/diakonosacc Music and Sound Effects by 8er41, GeriArt and Frolickingdp1 on www.pixabay.com/